Lead Product(s) : Abituzumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : SFJ Pharmaceuticals | Merck Group | AIO-Studien-gGmbH | Academic and Community Cancer Research United
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 28, 2018
Lead Product(s) : Abituzumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : SFJ Pharmaceuticals | Merck Group | AIO-Studien-gGmbH | Academic and Community Cancer Research United
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abituzumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 20, 2016
Lead Product(s) : Abituzumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abituzumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 26, 2011
Lead Product(s) : Abituzumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abituzumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of EMD525797 in Solid Tumor Patients in Japan
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 01, 2011
Lead Product(s) : Abituzumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable